Journal
LARYNGOSCOPE
Volume 130, Issue 4, Pages E140-E143Publisher
WILEY
DOI: 10.1002/lary.28038
Keywords
Pembrolizumab; mucositis; laryngeal edema
Ask authors/readers for more resources
Pembrolizumab, an anti-PD-1 checkpoint inhibitor, is used in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who have received prior therapy with a platinum-based regimen. As a monotherapy, it is generally well tolerated, but a small percentage of patients may develop immune-mediated inflammatory reactions. We report a case of mucositis and laryngeal edema in a patient on pembrolizumab and review the literature. Laryngoscope, 130:E140-E143, 2020
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available